Gene expression profiles of NO- and HNO-donor treated breast cancer cells: Insights into tumor response and resistance pathways

Robert Y S Cheng, Debashree Basudhar, Lisa A. Ridnour, Julie L. Heinecke, Aparna H. Kesarwala, Sharon Glynn, Christopher H. Switzer, Stefan Ambs, Katrina M Miranda, David A. Wink

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Nitric oxide (NO) synthase 2 (NOS2), a major inflammatory protein, modulates disease progression via NO in a number of pathologies, including cancer. The role of NOS2-derived NO is not only flux-dependent, which is higher in mouse vs human cells, but also varies based on spatial and temporal distribution both within tumor cells and in the tumor microenvironment. NO donors have been utilized to mimic NO flux conditions and to investigate the effects of varied NO concentrations. As a wide range of effects mediated by NO and other nitrogen oxides such as nitroxyl (HNO) have been elucidated, multiple NO- and HNO-releasing compounds have been developed as potential therapeutics, including as tumor modulators. One of the challenges is to determine differences in biomarker expression from extracellular vs intracellular generation of NO or HNO. Taking advantage of new NO and HNO releasing agents, we have characterized the gene expression profile of estrogen receptor-negative human breast cancer (MDA-MB-231) cells following exposure to aspirin, the NO donor DEA/NO, the HNO donor IPA/NO andtheir intracellularly-activated prodrug conjugates DEA/NO-aspirin and IPA/NO-aspirin. Comparison of the gene expression profiles demonstrated that several genes were uniquely expressed with respect to NO or HNO, such as miR-21, HSP70, cystathionine γ-lyase and IL24. These findings provide insight into targets and pathways that could be therapeutically exploited by the redox related species NO and HNO.

Original languageEnglish (US)
Pages (from-to)17-28
Number of pages12
JournalNitric Oxide - Biology and Chemistry
Volume43
DOIs
StatePublished - Dec 1 2014

Fingerprint

Nitric Oxide Donors
Transcriptome
Gene expression
Tumors
Nitric Oxide
Cells
Breast Neoplasms
Neoplasms
Aspirin
Nitric Oxide Synthase
Cystathionine
Nitrogen Oxides
Fluxes
Lyases
Tumor Microenvironment
Prodrugs
Biomarkers
Pathology
Estrogen Receptors
Oxidation-Reduction

Keywords

  • Breast cancer
  • Cancer biology
  • Cell signaling
  • Nitric oxide
  • Nitric oxide synthase
  • Nitroxyl

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Cancer Research
  • Physiology

Cite this

Gene expression profiles of NO- and HNO-donor treated breast cancer cells : Insights into tumor response and resistance pathways. / Cheng, Robert Y S; Basudhar, Debashree; Ridnour, Lisa A.; Heinecke, Julie L.; Kesarwala, Aparna H.; Glynn, Sharon; Switzer, Christopher H.; Ambs, Stefan; Miranda, Katrina M; Wink, David A.

In: Nitric Oxide - Biology and Chemistry, Vol. 43, 01.12.2014, p. 17-28.

Research output: Contribution to journalArticle

Cheng, Robert Y S ; Basudhar, Debashree ; Ridnour, Lisa A. ; Heinecke, Julie L. ; Kesarwala, Aparna H. ; Glynn, Sharon ; Switzer, Christopher H. ; Ambs, Stefan ; Miranda, Katrina M ; Wink, David A. / Gene expression profiles of NO- and HNO-donor treated breast cancer cells : Insights into tumor response and resistance pathways. In: Nitric Oxide - Biology and Chemistry. 2014 ; Vol. 43. pp. 17-28.
@article{b16e75402b6942aba9c3749ea006999a,
title = "Gene expression profiles of NO- and HNO-donor treated breast cancer cells: Insights into tumor response and resistance pathways",
abstract = "Nitric oxide (NO) synthase 2 (NOS2), a major inflammatory protein, modulates disease progression via NO in a number of pathologies, including cancer. The role of NOS2-derived NO is not only flux-dependent, which is higher in mouse vs human cells, but also varies based on spatial and temporal distribution both within tumor cells and in the tumor microenvironment. NO donors have been utilized to mimic NO flux conditions and to investigate the effects of varied NO concentrations. As a wide range of effects mediated by NO and other nitrogen oxides such as nitroxyl (HNO) have been elucidated, multiple NO- and HNO-releasing compounds have been developed as potential therapeutics, including as tumor modulators. One of the challenges is to determine differences in biomarker expression from extracellular vs intracellular generation of NO or HNO. Taking advantage of new NO and HNO releasing agents, we have characterized the gene expression profile of estrogen receptor-negative human breast cancer (MDA-MB-231) cells following exposure to aspirin, the NO donor DEA/NO, the HNO donor IPA/NO andtheir intracellularly-activated prodrug conjugates DEA/NO-aspirin and IPA/NO-aspirin. Comparison of the gene expression profiles demonstrated that several genes were uniquely expressed with respect to NO or HNO, such as miR-21, HSP70, cystathionine γ-lyase and IL24. These findings provide insight into targets and pathways that could be therapeutically exploited by the redox related species NO and HNO.",
keywords = "Breast cancer, Cancer biology, Cell signaling, Nitric oxide, Nitric oxide synthase, Nitroxyl",
author = "Cheng, {Robert Y S} and Debashree Basudhar and Ridnour, {Lisa A.} and Heinecke, {Julie L.} and Kesarwala, {Aparna H.} and Sharon Glynn and Switzer, {Christopher H.} and Stefan Ambs and Miranda, {Katrina M} and Wink, {David A.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.niox.2014.08.003",
language = "English (US)",
volume = "43",
pages = "17--28",
journal = "Nitric Oxide - Biology and Chemistry",
issn = "1089-8603",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Gene expression profiles of NO- and HNO-donor treated breast cancer cells

T2 - Insights into tumor response and resistance pathways

AU - Cheng, Robert Y S

AU - Basudhar, Debashree

AU - Ridnour, Lisa A.

AU - Heinecke, Julie L.

AU - Kesarwala, Aparna H.

AU - Glynn, Sharon

AU - Switzer, Christopher H.

AU - Ambs, Stefan

AU - Miranda, Katrina M

AU - Wink, David A.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Nitric oxide (NO) synthase 2 (NOS2), a major inflammatory protein, modulates disease progression via NO in a number of pathologies, including cancer. The role of NOS2-derived NO is not only flux-dependent, which is higher in mouse vs human cells, but also varies based on spatial and temporal distribution both within tumor cells and in the tumor microenvironment. NO donors have been utilized to mimic NO flux conditions and to investigate the effects of varied NO concentrations. As a wide range of effects mediated by NO and other nitrogen oxides such as nitroxyl (HNO) have been elucidated, multiple NO- and HNO-releasing compounds have been developed as potential therapeutics, including as tumor modulators. One of the challenges is to determine differences in biomarker expression from extracellular vs intracellular generation of NO or HNO. Taking advantage of new NO and HNO releasing agents, we have characterized the gene expression profile of estrogen receptor-negative human breast cancer (MDA-MB-231) cells following exposure to aspirin, the NO donor DEA/NO, the HNO donor IPA/NO andtheir intracellularly-activated prodrug conjugates DEA/NO-aspirin and IPA/NO-aspirin. Comparison of the gene expression profiles demonstrated that several genes were uniquely expressed with respect to NO or HNO, such as miR-21, HSP70, cystathionine γ-lyase and IL24. These findings provide insight into targets and pathways that could be therapeutically exploited by the redox related species NO and HNO.

AB - Nitric oxide (NO) synthase 2 (NOS2), a major inflammatory protein, modulates disease progression via NO in a number of pathologies, including cancer. The role of NOS2-derived NO is not only flux-dependent, which is higher in mouse vs human cells, but also varies based on spatial and temporal distribution both within tumor cells and in the tumor microenvironment. NO donors have been utilized to mimic NO flux conditions and to investigate the effects of varied NO concentrations. As a wide range of effects mediated by NO and other nitrogen oxides such as nitroxyl (HNO) have been elucidated, multiple NO- and HNO-releasing compounds have been developed as potential therapeutics, including as tumor modulators. One of the challenges is to determine differences in biomarker expression from extracellular vs intracellular generation of NO or HNO. Taking advantage of new NO and HNO releasing agents, we have characterized the gene expression profile of estrogen receptor-negative human breast cancer (MDA-MB-231) cells following exposure to aspirin, the NO donor DEA/NO, the HNO donor IPA/NO andtheir intracellularly-activated prodrug conjugates DEA/NO-aspirin and IPA/NO-aspirin. Comparison of the gene expression profiles demonstrated that several genes were uniquely expressed with respect to NO or HNO, such as miR-21, HSP70, cystathionine γ-lyase and IL24. These findings provide insight into targets and pathways that could be therapeutically exploited by the redox related species NO and HNO.

KW - Breast cancer

KW - Cancer biology

KW - Cell signaling

KW - Nitric oxide

KW - Nitric oxide synthase

KW - Nitroxyl

UR - http://www.scopus.com/inward/record.url?scp=84913588785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913588785&partnerID=8YFLogxK

U2 - 10.1016/j.niox.2014.08.003

DO - 10.1016/j.niox.2014.08.003

M3 - Article

C2 - 25153034

AN - SCOPUS:84913588785

VL - 43

SP - 17

EP - 28

JO - Nitric Oxide - Biology and Chemistry

JF - Nitric Oxide - Biology and Chemistry

SN - 1089-8603

ER -